Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Prelude Therapeutics ( (PRLD) ).
On February 3, 2026, Prelude Therapeutics announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for PRT12396, a mutant-selective JAK2V617F inhibitor designed to treat certain myeloproliferative neoplasms, allowing the company to proceed with a Phase 1 study and positioning the drug as a potential new targeted option for patients with polycythemia vera and myelofibrosis. The open-label, multi-center trial, expected to begin dosing patients by the second quarter of 2026, marks a key milestone in Prelude’s strategic pivot toward its JAK2 and KAT6 programs and advances an asset that sits under an exclusive option agreement with Incyte, underscoring the company’s ambition to reshape the treatment landscape in myeloproliferative neoplasms and strengthen its standing in precision oncology.
The most recent analyst rating on (PRLD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Neutral.
The score is held down primarily by substantial ongoing losses, large cash burn, and a shrinking equity base. Offsetting that, the earnings call outlined credible pipeline milestones and a major Incyte deal that supports runway into 2027. Technically, the stock shows weak near-term momentum, and valuation is constrained by negative earnings and no dividend.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics is a precision oncology company developing innovative cancer medicines for areas of high unmet medical need. Its pipeline centers on highly selective KAT6A degraders and JAK2V617F mutant-selective inhibitors, and it is leveraging targeted protein degradation technology to create next-generation degrader antibody conjugates with novel payloads, aiming to extend precision medicine benefits across a broad range of cancer patients.
Average Trading Volume: 981,996
Technical Sentiment Signal: Buy
Current Market Cap: $104.7M
See more data about PRLD stock on TipRanks’ Stock Analysis page.